Customize
Quick Links

Accreditation/
Credit Designation

This activity is approved for AMA PRA Category 1 Credit™.

Physicians' Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669.

Acknowledgement of Commercial Support

This activity is supported by educational grants from Astellas, Genomic Health, Inc., and Medivation, Inc., a Pfizer company.

About
Accreditation
Privacy Policy
Terms & Conditions
Executive Board
Journal
Faculty Portal
Contact
Facebook
Twitter
LinkedIn
Google +
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2017
Physicians’ Education Resource ®, LLC.
All rights reserved.

New York GU™: 11th Annual Interdisciplinary Prostate Cancer Congress® and other Genitourinary Malignancies

New York GU™: 11th Annual Interdisciplinary Prostate Cancer Congress® and other Genitourinary Malignancies


March 24, 2018
Crowne Plaza® Times Square Manhattan
1605 Broadway (at 49th Street)
New York, NY 10019
Hotel Reservation Website


Overview

The congress will focus on key clinical topics in the management of genitourinary (GU) malignancies, including optimal use of chemotherapeutic and local therapies, androgen-deprivation therapies, targeted therapies, radiopharmaceuticals, and immunotherapies. Coverage will include discussions of prognostic/predictive marker application and proactive mitigation of predictable treatment-related adverse effects. Promising new and emerging data in the field will be explored, for example, combining and sequencing treatments across the disease continuum. Key questions concerning the application of landmark clinical trial data (eg, PSA screening, decision making for castrate-sensitive prostate cancer) will be answered during this program. New in 2018, the popular case-based panel discussions will highlight cases submitted by New York GU™ attendees.

Now in its 11th year, the 2018 New York GU™ meeting is not to be missed! The meeting will continue its legacy and tradition of providing clinicians with the valuable knowledge and confidence to maintain state-of-the-art care and optimize outcomes for patients with genitourinary malignancies.
 

Acknowledgement of Commercial Support

This activity is supported by educational grants from Astellas, Genomic Health, Inc., and Medivation, Inc., a Pfizer company.

Target Audience

This educational activity is directed toward medical, surgical, and radiation oncologists involved in the treatment of patients with genitourinary (GU) malignancies. Urologists, fellows, nurse practitioners, nurses, physician assistants, pharmacists, researchers, nuclear medicine physicians, and other healthcare professionals interested in the treatment of GU malignancies may also participate.

Learning Objectives

After this activity, participants should be better prepared to:

  • Outline the use of patient- and disease-specific characteristics to inform clinical decision-making in the management of patients with GU malignancies
  • Discuss current strategies and practice-changing evidence for the management of patients with GU malignancies across multiple lines of care
  • Explain how to proactively mitigate expected treatment-related toxicities associated with immunotherapeutic and targeted approaches to treat GU cancers
  • Apply emerging clinical trial data for the management of GU malignancies in the context of changing treatment paradigms in the field

Co-Chairs

Daniel P. Petrylak, MD
Professor of Medicine, Medical Oncology
Director, Prostate and GU Medical Oncology
Director, Prostate Cancer Translational Research Program
Yale Cancer Center
New Haven, CT

Leonard G. Gomella, MD, FACS
The Bernard W. Godwin Professor of Prostate Cancer
Chairman, Department of Urology
Associate Director, Jefferson Kimmel Cancer Center
Clinical Director Jefferson Kimmel Cancer Center Network
Thomas Jefferson University
Philadelphia, PA







Become a Member

Forgot Password?
Calendar of Events
SUNMONTUESWEDTHURSFRISAT
     12
3456789
10111213141516
17181920212223
24252627282930
31
Filter By